Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo

AWARD-PEDS results presented at ADA's 82nd Scientific Sessions ® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population INDIANAPOLIS , June 4, 2022 /PRNewswire/ -- In the phase 3